Back to top
more

Owens & Minor (OMI)

(Delayed Data from NYSE)

$6.90 USD

6.90
1,294,632

+0.33 (5.02%)

Updated Aug 4, 2025 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (155 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Bruker (BRKR) to Improve Spatial Biology With New Launch

by Zacks Equity Research

Bruker's (BRKR) acquired company, Canopy Biosciences, introduced its next generation of ChipCytometry instrumentation for spatial biology.

Zacks Equity Research

Bruker (BRKR), Newomics to Co-Market Joint MnESI-MS Platform

by Zacks Equity Research

The maxis II and timsTOF Pro 2 mass spectrometers from Bruker (BRKR) will be marketed with Newomics's MnESI product line.

Zacks Equity Research

Here's Why You Should Retain Haemonetics (HAE) Stock for Now

by Zacks Equity Research

Investors are optimistic about Haemonetics (HAE) given strong recovery across businesses and strength in plasma franchise.

Zacks Equity Research

McKesson (MCK) Up 5.1% Since Q3 Earnings: What's Driving It?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) robust segmental performance and raised earnings outlook for fiscal 2022.

Zacks Equity Research

Here's Why You Should Invest In Bruker (BRKR) Stock Now

by Zacks Equity Research

Investors are optimistic about Bruker's (BRKR) better-than-expected revenues and robust segmental performance.

Zacks Equity Research

Are These Medical Stocks Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Abbott (ABT) Gets FDA Approval for CardioMEMS HF System

by Zacks Equity Research

Abbott's (ABT) CardioMEMS HF System will enable physicians to monitor for early warning signs of worsening heart failure before it progresses to a later stage.

Zacks Equity Research

Here's Why You Should Hold on to STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS (STE) on its better-than-expected earnings in the fiscal third quarter and the ongoing integration of the Cantel Medical business.

Zacks Equity Research

Here's Why You Should Hold on to IDEXX (IDXX) Stock for Now

by Zacks Equity Research

Robust domestic and international performances by the CAG arm are driving IDEXX's (IDXX) fourth-quarter top line.

Zacks Equity Research

Tandem Diabetes (TNDM) to Offer Insulin Delivery With Smartphone

by Zacks Equity Research

Tandem Diabetes' (TNDM) t:connect is the first-ever app on both iOS and Android operating systems to receive FDA clearance for insulin delivery from a personal smartphone.

Zacks Equity Research

OPKO's (OPK) NGENLA to Offer GHD Treatment in European Union

by Zacks Equity Research

OPKO's (OPK) marketing authorization for NGENLA in the European Union stands to benefit children and adolescents affected by growth hormone deficiency.

Zacks Equity Research

Here's Why You Should Hold on to Thermo Fisher (TMO) Stock Now

by Zacks Equity Research

Investors are optimistic about Thermo Fisher's (TMO) better-than-expected fourth-quarter results and impressive COVID-19 response-related revenues.

Zacks Equity Research

Should Value Investors Buy These Medical Stocks?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Here's Why You Should Retain Bio-Rad (BIO) Stock for Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad's (BIO) strong growth within Life Science and Clinical Diagnostics segments across all regions.

Zacks Equity Research

Medtronic (MDT) Reports First Procedure in Europe With Hugo RAS

by Zacks Equity Research

Medtronic's (MDT) Hugo RAS system was utilized to perform robotic prostatectomy at OLV Hospital in Aalst, Belgium.

Zacks Equity Research

Abbott's (ABT) Diabetes Arm Booms, Neuromodulation Sales Soft

by Zacks Equity Research

Even though COVID-19 case rates are surging in the United States and other geographies, Abbott is seeing growth in its consumer-facing businesses like nutrition, EPD and diabetes care.

Zacks Equity Research

Here's Why You Should Hold on to Tandem Diabetes (TNDM) for Now

by Zacks Equity Research

Investors are optimistic about Tandem Diabetes' (TNDM) t:slim X2 technology and greater use of Control-IQ technology.

Zacks Equity Research

Are Investors Undervaluing These Medical Stocks Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Medtronic (MDT) Undertakes Investment to Advance STEM Education

by Zacks Equity Research

The Medtronic Foundation, solely funded by Medtronic plc (MDT), entered into 13 new partnerships to bridge the inequity in STEM education among underrepresented and underserved communities.

Zacks Equity Research

Is Immunic (IMUX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Immunic (IMUX) and Owens & Minor (OMI) have performed compared to their sector so far this year.

Zacks Equity Research

Are Investors Undervaluing These Medical Stocks Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

What Makes Owens & Minor (OMI) a Good Fit for "Trend Investing"

by Zacks Equity Research

Owens & Minor (OMI) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Zacks Equity Research

Company News for Jan 11, 2022

by Zacks Equity Research

Companies in The News Are: CMC,AZZ,ZNGA,TTWO,APR,OMI

Zacks Equity Research

All You Need to Know About Owens & Minor (OMI) Rating Upgrade to Buy

by Zacks Equity Research

Owens & Minor (OMI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Are These Medical Stocks Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.